Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
about
Ventilator-associated pneumonia: diagnosis, treatment, and preventionClinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs.Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrationsGuidelines on antimicrobial chemotherapy for prevention and treatment of infections in the intensive care unit.In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBHow do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionIssues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MICPharmacokinetic/pharmacodynamic evaluation of anti-infective agents.Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infectionDefining, treating and preventing hospital acquired pneumonia: European perspective.Quinolones: action and resistance updated.A Diffusion-Based and Dynamic 3D-Printed Device That Enables Parallel in Vitro Pharmacokinetic Profiling of MoleculesPharmacokinetic studies in patients on continuous renal replacement therapies.The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration.Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.Early clinical assessment of the antimicrobial activity of finafloxacin compared to ciprofloxacin in sub-sets of microbiologically characterized isolates.
P2860
Q29012676-397F6602-89EF-4924-99F2-B475B46A7B16Q33843878-91189438-3180-4CF7-B84A-3226C3E89F7AQ33981343-3E767F07-07FD-4DDA-88D6-F306FB849884Q33982991-062CFC0D-5FA2-4CBC-BC33-94DF16B28751Q33983182-2FD69914-ADAB-4D01-B581-51DF579BFAF8Q34589960-18A92D0E-9092-4C09-896C-9794827AEC7FQ34591451-D0A4AB9C-81FD-48FD-89AA-618C4229D5B1Q34894900-45E3FEE1-160A-49E2-A688-075B55332DD2Q34937444-53CA88A7-9F5D-4999-91D9-3523FA31629AQ35637864-BB76884F-2B85-4C78-9BB1-345B6B18CF60Q36162355-8FED98D6-0A19-48A5-B9E4-FA569CE1D9C1Q36342239-31171C62-5DB9-46B6-8011-DA13348F651BQ36554698-11DFD47A-D082-493D-BB1B-5300488F382DQ36879791-9DCCE1D7-59A8-4F0A-959A-65D15EA9E490Q37319452-B0D67BEF-9167-4A95-B68C-268553507DC7Q37595559-251E9B89-BC51-4957-9444-6FC8D7FA9385Q37630801-F61D7938-BF3B-486E-93AC-730F9D056171Q43634385-4B46C76D-53D4-4588-84BB-4704D45014E8Q45170003-5F317526-8F50-4F95-9D5B-29AE934D55B0Q46254071-C186624E-8AC5-40EF-BE9C-544A5817EB89Q46728767-62B3A6E9-A4C9-4640-97FE-F3C3C5B09530Q50020716-9A8CCAB2-B690-4F52-964A-AFCB0CA62F80
P2860
Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Antimicrobial action and pharm ...... efficacy and avoid resistance.
@ast
Antimicrobial action and pharm ...... efficacy and avoid resistance.
@en
type
label
Antimicrobial action and pharm ...... efficacy and avoid resistance.
@ast
Antimicrobial action and pharm ...... efficacy and avoid resistance.
@en
prefLabel
Antimicrobial action and pharm ...... efficacy and avoid resistance.
@ast
Antimicrobial action and pharm ...... efficacy and avoid resistance.
@en
P2860
P921
P1476
Antimicrobial action and pharm ...... efficacy and avoid resistance.
@en
P2093
Schentag JJ
P2860
P304
P356
10.1179/JOC.1999.11.6.426
P577
1999-12-01T00:00:00Z